| abstract |
Provided is a cancer antigen peptide that does not require HLA type inspection, that is not restricted to patients having a specific HLA type, and that can be administered to a wide range of cancer patients as a cancer peptide vaccine. A peptide having 5 linked CTL epitopes, the peptide being obtained by linking, via a linker, 5 CTL epitope peptides selected from a group of CTL epitope peptides reported to be capable of CTL induction and derived from tumor antigen molecules. |